The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Jill Biden’s visit to Hollings brings awareness to mammograms missed during the pandemic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In mid-October, First Lady Dr. Jill Biden asked to visit the Hollings Cancer Center at the Medical University of South Carolina to help raise awareness of the need for breast cancer screening, education, and treatment—particularly among underserved minority women. 

She expressed concern that the number of routine mammograms had dropped dramatically during the COVID pandemic, particularly among this often-neglected cohort. 

We are all concerned that while fewer Black and minority women in South Carolina are diagnosed with breast cancer, a larger number of them die of the disease. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Raymond N. DuBois, MD, PhD
Director, Hollings Cancer Center and Dean of Medicine, The Medical University of South Carolina
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III study shows

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. 
Clinical Roundup

AI improves breast cancer diagnosis

Artificial Intelligence can improve breast cancer detection and reduce workload on physicians, according to a new study featuring over 461,000 women. The research published in the journal Nature Medicine looked at integrating an AI tool as part of a national screening program for women without symptoms of breast cancer in Germany.
Clinical Roundup

Ibrance + standard-of-care extends median PFS by over 15 months in HR+, HER2+ metastatic breast cancer, phase III trial shows

The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer. 
Byline
Raymond N. DuBois, MD, PhD
Director, Hollings Cancer Center and Dean of Medicine, The Medical University of South Carolina
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account